News

Ferring Pharmaceuticals will initially market Lysteda in the US, and is evaluating opportunities in other markets. Lysteda oral tablets received approval on November 13, 2009 following a priority

Mr Weis said that abnormal signaling contributes to many diseases such as cancer and diabetes, so the method can be used to develop new drugs for the diseases.

CLC bio said that its high-throughput sequence analysis infrastructure is expected to empower both OSC’s scientists and OSC’s Genome Network Analysis Service (GeNAS) with a user-friendly and fast

Soligenix said that the new patent’s main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower

The recommendations are patient centered, and were developed following a call for such standards by the Institute of Medicine (IOM) on the issue of health literacy. The recommendations

BD Biosciences said that the system’s modular architecture along with exchangeable detector options, hands-on controls, and sorting options make it adaptable to a wide variety of site and

Dr Novak will be responsible for Fate’s drug discovery and development activities focused on advancing its pipeline of stem cell modulators, small molecules or biologics that guide cell

Neomycin Sulfate tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomyces fradiae. Neomycin is an aminoglycoside antibiotic.

Intellipharmaceutics’ application will now proceed to full review by the FDA. Intellipharmaceutics aims to develop its pipeline products to an advanced stage, and will now seek a commercialization